SCR1693

SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus[1][2][3].

Product Specifications

CAS Number

[1442559-20-7]

UNSPSC

12352005

Target

Akt; Amyloid-β; Calcium Channel; Cholinesterase (ChE) ; GSK-3; Phosphatase; PKA; Tau Protein

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neurodegeneration

Field of Research

Metabolic Disease; Neurological Disease

Smiles

O=C(C1=C(C)N=C2NC3=C(CC(C)(CC3)C)C(N)=C2C1C4=C(Cl)C=CC=C4)OCC

Molecular Formula

C24H28ClN3O2

Molecular Weight

425.95

References & Citations

[1]Wang XL, et al. A novel tacrine-dihydropyridine hybrid (-) SCR1693 induces tau dephosphorylation and inhibits Aβ generation in cells. Eur J Pharmacol. 2015 May 5;754:134-9.|[2]Bi A, et al. SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits. Neuropharmacology. 2020 May 15;168:108027. |[3]Zhang Z, et al. A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function. Psychopharmacology (Berl) . 2016 Feb;233 (4) :599-613.